SAGE Therapeutics Initiates Phase 1/2 Trial Of SAGE-547 In Status Epilepticus

CAMBRIDGE, Mass.--(BUSINESS WIRE)--SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening and rare central nervous system (CNS) disorders, today announced dose initiation of the first patient in a Phase 1/2 clinical trial of SAGE-547, a neuroactive steroid, in super-refractory status epilepticus (SRSE), a critical condition in which the brain is in a state of persistent seizure. The trial is designed to evaluate the safety, tolerability and efficacy of SAGE-547 as an adjunctive therapy for the treatment of SRSE.

Help employers find you! Check out all the jobs and post your resume.